Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239752 | 0.84 | TLR7 (0.50) | ADORA1HPGDADORA2BADORA3ADORA2A | |
| SCHEMBL3114744 | 0.82 | ADORA2B (0.48) | ADORA1ADORA2BADORA3ADORA2AMEN1 | |
| SCHEMBL7031457 | 0.81 | SIRT1 (0.55) | ADORA1ADORA2BADORA3ADORA2A | |
| SCHEMBL3119443 | 0.80 | SIRT1 (0.54) | ADORA1ADORA2BADORA3ADORA2A | |
| SCHEMBL3120828 | 0.79 | SMN1; SMN2 (0.51) | ADORA1HPGDADORA2BADORA3ADORA2A | |
| SCHEMBL13247926 | 0.79 | ADORA2B (0.53) | ADORA1ADORA2BADORA3ADORA2A | |
| SCHEMBL13247927 | 0.79 | ADORA2B (0.53) | ADORA1ADORA2BADORA3ADORA2A | |
| SCHEMBL3115564 | 0.79 | ADORA1 (0.48) | ADORA1ADORA2BADORA3ADORA2A | |
| SCHEMBL3112308 | 0.79 | ADORA1 (0.47) | ADORA1ADORA2BADORA3ADORA2A | |
| SCHEMBL3114117 | 0.79 | ADORA2A (0.47) | ADORA1ADORA2BADORA3ADORA2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | XDH, GPR84, GPR88 | RXFP1 297/4885ADORA1 32/4885HPGD 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.